Our goal is to engage and enhance the immune system’s natural ability to fight even difficult-to-treat diseases, creating better treatments for better outcomes.
Clinical trial volunteers play a critical role in helping us achieve this goal, furthering our research while also being among the first to have access to potential new therapies. Together, we can find better ways to prevent, diagnose, and treat disease.
ANKTIVA® (N-803) is being studied in several clinical trials for other types of cancer including different stages of non-muscle invasive bladder cancer. If you were recently diagnosed with NMIBC and have not received prior BCG treatment for the disease or have not received BCG in the last 3 years, you might qualify for our QUILT 2.005 clinical trial. Please complete the form below to be referred to a trial site for more information.